Monopar Q1 net loss $2.6M, cash $54.6M; ALXN1840 NDA planned early 2026

Monopar Therapeutics

Cash $54.6M as of March 31, 2025; expected runway through Dec 2026 for NDA and trials.
Net loss $2.6M ($0.38/sh) vs $1.6M ($0.51/sh) YoY; R&D expense rose 70% to $1.643M.
ALXN1840 data presented at EASL; NDA submission to FDA planned early 2026.
MNPR-101-Zr and MNPR-101-Lu Phase 1 trials active in Australia; preclinical Ac-225 program advancing.
G&A expense doubled to $1.578M, driven by stock option grants and higher personnel costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.